Global Information
회사소개 | 문의 | 비교리스트

비낭포성 섬유증 기관지확장증(NCFB) : 역학적 예측(-2030년)

Non-cystic Fibrosis Bronchiectasis (NCFB) - Epidemiology Forecast to 2030

리서치사 DelveInsight Business Research LLP
발행일 2020년 05월 상품 코드 934338
페이지 정보 영문 100 Pages
가격
US $ 3,750 ₩ 4,314,000 PDF by E-mail (Single User License)
US $ 7,500 ₩ 8,628,000 PDF by E-mail (Site License)
US $ 11,250 ₩ 12,943,000 PDF by E-mail (Global License)


비낭포성 섬유증 기관지확장증(NCFB) : 역학적 예측(-2030년) Non-cystic Fibrosis Bronchiectasis (NCFB) - Epidemiology Forecast to 2030
발행일 : 2020년 05월 페이지 정보 : 영문 100 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

세계 주요 국가(미국, 유럽 주요 5개국(EU5 : 프랑스·독일·이탈리아·스페인·영국), 일본)의 비낭포성 섬유증 기관지확장증(NCFB : Non-cystic Fibrosis Bronchiectasis) 역학적 동향과 향후 전망에 대해 분석하여 전해드립니다.

제1장 주요 인사이트

제2장 비낭포성 섬유증 기관지확장증(NCFB)의 개요

  • NCFB의 환자 점유율 : 2017년
  • NCFB의 환자 점유율 : 2030년

제3장 질환 배경과 개요

  • 서론
  • 병기와 증상
  • 증상
  • 병태생리
  • 진단
  • 예후

제4장 치료와 관리

제5장 역학과 환자 인구

  • 주요 조사 결과
  • NCFB의 환자·환자 총수(주요 7개국의 경우)

제6장 국가별 분석

  • 미국
    • NCFB의 환자 수
    • NCFB의 진단 환자 수
    • NCFB의 진단 환자 수 : 성별
    • NCFB의 진단 환자 수 : 중증도별
    • NCFB 환자의 병인
    • NCFB 환자의 미생물학적 동향
  • 유럽 5개국
    • 독일
    • 프랑스
    • 이탈리아
    • 스페인
    • 영국
  • 일본
    • NCFB의 환자 수

제7장 미충족 요구

제8장 부록

제9장 DelveInsight의 서비스 내용

제10장 면책사항

제11장 : DelveInsight 소개

KSA 20.06.02

List of Tables

  • Table 1: Conditions associated with the development of bronchiectasis
  • Table 2: Total Prevalent Population of NCFB in 7MM (2017-2030)
  • Table 3: Prevalent Population of NCFB in the United States (2017-2030)
  • Table 4: Diagnosed Prevalent Population of NCFB in the United States (2017-2030)
  • Table 5: Gender Specific Diagnosed Prevalence of NCFB in the United States (2017-2030)
  • Table 6: Severity Specific Diagnosed prevalence NCFB in the United States (2017-2030)
  • Table 7: Etiology associated with NCFB in the United States (2017-2030)
  • Table 8: Microbiology of NCFB patients in the United States (2017-2030)
  • Table 9: Prevalent Population of NCFB in the Germany (2017-2030)
  • Table 10: Diagnosed Prevalent Population of NCFB in Germany (2017-2030)
  • Table 11: Gender Specific Diagnosed Prevalence of NCFB in Germany (2017-2030)
  • Table 12: Severity Specific Diagnosed prevalence NCFB in Germany (2017-2030)
  • Table 13: Etiology associated with NCFB in the Germany (2017-2030)
  • Table 14: Microbiology of NCFB patients in Germany (2017-2030)
  • Table 15: Prevalent Population of NCFB in France (2017-2030)
  • Table 16: Diagnosed Prevalent Population of NCFB in France (2017-2030)
  • Table 17: Gender Specific Diagnosed Prevalence of NCFB in France (2017-2030)
  • Table 18: Severity Specific Diagnosed prevalence NCFB in France (2017-2030)
  • Table 19: Etiology associated with NCFB in France (2017-2030)
  • Table 20: Microbiology of NCFB patients in France (2017-2030)
  • Table 21: Prevalent Population of NCFB in Italy (2017-2030)
  • Table 22: Diagnosed Prevalent Population of NCFB in Italy (2017-2030)
  • Table 23: Gender Specific Diagnosed Prevalence of NCFB in Italy (2017-2030)
  • Table 24: Severity Specific Diagnosed prevalence NCFB in Italy (2017-2030)
  • Table 25: Etiology associated with NCFB in Italy (2017-2030)
  • Table 26: Microbiology of NCFB patients in Italy (2017-2030)
  • Table 27: Prevalent Population of NCFB in the Spain (2017-2030)
  • Table 28: Diagnosed Prevalent Population of NCFB in Spain (2017-2030)
  • Table 29: Gender Specific Diagnosed Prevalence of NCFB in Spain (2017-2030)
  • Table 30: Severity Specific Diagnosed prevalence NCFB in Spain (2017-2030)
  • Table 31: Etiology associated with NCFB in Spain (2017-2030)
  • Table 32: Microbiology of NCFB patients in Spain (2017-2030)
  • Table 33: Prevalent Population of NCFB in the UK (2017-2030)
  • Table 34: Diagnosed Prevalent Population of NCFB in the UK (2017-2030)
  • Table 35: Gender Specific Diagnosed Prevalence of NCFB in the UK (2017-2030)
  • Table 36: Severity Specific Diagnosed prevalence NCFB in the UK (2017-2030)
  • Table 37: Etiology associated with NCFB in the UK (2017-2030)
  • Table 38: Microbiology of NCFB patients in the UK (2017-2030)
  • Table 39: Prevalent Population of NCFB in Japan (2017-2030)
  • Table 40: Diagnosed Prevalent Population of NCFB in Japan (2017-2030)
  • Table 41: Gender Specific Diagnosed Prevalence of NCFB in Japan (2017-2030)
  • Table 42: Severity Specific Diagnosed prevalence NCFB in Japan (2017-2030)
  • Table 43: Etiology associated with NCFB in Japan (2017-2030)
  • Table 44: Microbiology of NCFB patients in Japan (2017-2030)

List of Figures

  • Figure 1: Common symptoms associated with non-CF bronchiectasis
  • Figure 2: Morphology of healthy and dilated bronchi
  • Figure 3: Representation of the cycle that leads to the development of bronchiectasis, as described by Cole
  • Figure 4: Airway obstruction, impaired mucociliary clearance, and other mechanisms promoting bronchiectasis
  • Figure 5: Algorithm for the diagnosis and etiologic investigation of bronchiectasis
  • Figure 6: Algorithm for the therapeutic management of stable bronchiectasis patients
  • Figure 7: Total Prevalent Population of NCFB in 7 MM (2017-2030)
  • Figure 8: Prevalent Population of NCFB in the United States (2017-2030)
  • Figure 9: Diagnosed Population of NCFB in the United States (2017-2030)
  • Figure 10: Gender Specific Diagnosed Prevalence of NCFB in the United States (2017-2030)
  • Figure 11: Severity Specific Diagnosed prevalence NCFB in the United States (2017-2030)
  • Figure 12: Etiology associated with NCFB in the United States (2017-2030)
  • Figure 13: Microbiology of NCFB patients in the United States (2017-2030)
  • Figure 14: Prevalent Population of NCFB in Germany (2017-2030)
  • Figure 15: Diagnosed Population of NCFB in Germany (2017-2030)
  • Figure 16: Gender Specific Diagnosed Prevalence of NCFB in Germany (2017-2030)
  • Figure 17: Severity Specific Diagnosed prevalence NCFB in Germany (2017-2030)
  • Figure 18: Etiology associated with NCFB in the Germany (2017-2030)
  • Figure 19: Microbiology of NCFB patients in Germany (2017-2030)
  • Figure 20: Prevalent Population of NCFB in France (2017-2030)
  • Figure 21: Diagnosed Population of NCFB in France (2017-2030)
  • Figure 22: Gender Specific Diagnosed Prevalence of NCFB in France (2017-2030)
  • Figure 23: Severity Specific Diagnosed prevalence NCFB in France (2017-2030)
  • Figure 24: Etiology associated with NCFB in France (2017-2030)
  • Figure 25: Microbiology of NCFB patients in France (2017-2030)
  • Figure 26: Prevalent Population of NCFB in Italy (2017-2030)
  • Figure 27: Diagnosed Population of NCFB in Italy (2017-2030)
  • Figure 28: Gender Specific Diagnosed Prevalence of NCFB in Italy (2017-2030)
  • Figure 29: Severity Specific Diagnosed prevalence NCFB in Italy (2017-2030)
  • Figure 30: Etiology associated with NCFB in Italy (2017-2030)
  • Figure 31: Microbiology of NCFB patients in Italy (2017-2030)
  • Figure 32: Prevalent Population of NCFB in Spain (2017-2030)
  • Figure 33: Diagnosed Population of NCFB in Spain (2017-2030)
  • Figure 34: Gender Specific Diagnosed Prevalence of NCFB in Spain (2017-2030)
  • Figure 35: Severity Specific Diagnosed prevalence NCFB in Spain (2017-2030)
  • Figure 36: Etiology associated with NCFB in Spain (2017-2030)
  • Figure 37: Microbiology of NCFB patients in Spain (2017-2030)
  • Figure 38: Prevalent Population of NCFB in the UK (2017-2030)
  • Figure 39: Diagnosed Population of NCFB in the UK (2017-2030)
  • Figure 40: Gender Specific Diagnosed Prevalence of NCFB in the UK (2017-2030)
  • Figure 41: Severity Specific Diagnosed prevalence NCFB in the UK (2017-2030)
  • Figure 42: Etiology associated with NCFB in the UK (2017-2030)
  • Figure 43: Microbiology of NCFB patients in the UK (2017-2030)
  • Figure 44: Prevalent Population of NCFB in Japan (2017-2030)
  • Figure 45: Diagnosed Population of NCFB in Japan (2017-2030)
  • Figure 46: Gender Specific Diagnosed Prevalence of NCFB in Japan (2017-2030)
  • Figure 47: Severity Specific Diagnosed prevalence NCFB in Japan (2017-2030)
  • Figure 48: Etiology associated with NCFB in Japan (2017-2030)
  • Figure 49: Microbiology of NCFB patients in Japan (2017-2030)
  • Figure 50: Unmet Needs

DelveInsight's 'Non-cystic fibrosis bronchiectasis (NCFB) - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Non-cystic fibrosis bronchiectasis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Non-cystic fibrosis bronchiectasis (NCFB) Understanding

Bronchiectasis is a chronic inflammatory lung disease. It is characterized by permanent dilatation of the bronchial tree which leads to chronic sputum production and impaired bacterial clearance. The affected parts of the lungs develop a vicious cycle of failed pathogen clearance leading to frequent infections, chronic inflammation, and ongoing structural damage. The main symptoms are daily cough, daily sputum production, and frequent respiratory infections. In patients without cystic fibrosis, the condition is known as non-cystic fibrosis bronchiectasis (NCFB).

Non-cystic fibrosis bronchiectasis Epidemiology Perspective by DelveInsight

The Non-cystic fibrosis bronchiectasis epidemiology division provides the insights about historical and current patient pool and forecasted trend for each seven major countries. The Non-cystic fibrosis bronchiectasis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Non-cystic fibrosis bronchiectasis epidemiology is segmented by Total Prevalence, Diagnosed Population, Etiology associated with NCFB, Gender-specific Prevalent Population, Severity and Microbiology of NCFB covering the US, EU5 countries (Germany, Spain, Italy, France, and the UK) and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Non-cystic fibrosis bronchiectasis Detailed Epidemiology Segmentation

The Non-cystic fibrosis bronchiectasis epidemiology covered in the report provides historical as well as forecasted epidemiology {Total Prevalence, Diagnosed Population, Etiology associated with NCFB, Gender-specific Prevalent Population, Severity and Microbiology of NCFB} scenario of Non-cystic fibrosis bronchiectasis in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Non-cystic fibrosis bronchiectasis report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The Non-cystic fibrosis bronchiectasis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Non-cystic fibrosis bronchiectasis Epidemiology Report and Model provide an overview of the risk factors and global trends of Non-cystic fibrosis bronchiectasis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Non-cystic fibrosis bronchiectasis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK) and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Non-cystic fibrosis bronchiectasis
  • The report provides the segmentation of the Non-cystic fibrosis bronchiectasis epidemiology by Etiology associated with NCFB in 7MM
  • The report provides the segmentation of the Non-cystic fibrosis bronchiectasis epidemiology by Microbiology of NCFB in 7MM

Report Highlights:

  • 11-Year Forecast of Non-cystic fibrosis bronchiectasis epidemiology
  • 7MM Coverage
  • Total Prevalent Cases of Non-cystic fibrosis bronchiectasis
  • Prevalent Cases according to segmentation: Etiology, Microbiology, Severity and Gender
  • Diagnosed cases of NCFB

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Non-cystic fibrosis bronchiectasis?
  • What are the key findings pertaining to the Non-cystic fibrosis bronchiectasis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Non-cystic fibrosis bronchiectasis across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Non-cystic fibrosis bronchiectasis?
  • What are the current available treatments of Non-cystic fibrosis bronchiectasis?

Reasons to buy:

The Non-cystic fibrosis bronchiectasis Epidemiology report will allow the user to -

  • Develop business strategies by understanding the trends shaping and driving the global Non-cystic fibrosis bronchiectasis market
  • Quantify patient populations in the global Non-cystic fibrosis bronchiectasis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Non-cystic fibrosis bronchiectasis therapeutics in each of the markets covered
  • Understand the magnitude of Non-cystic fibrosis bronchiectasis population by its Sub-Types
  • The Non-cystic fibrosis bronchiectasis epidemiology report and model were written and developed by Masters and PhD level epidemiologists
  • The Non-cystic fibrosis bronchiectasis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

Although NCFB was once a very uncommon diagnosis, in the last two decades, its prevalence has been increasing, making it more likely that primary care clinicians will encounter these patients in their practice.

The precise prevalence of NCFB is difficult to determine because estimates vary among populations, but studies report a prevalence ranging from 486 to 1106 per 100,000 persons with an incidence that appears to be rising, particularly in women and older individuals.

Bronchiectasis may be caused by several factors, including previous severe respiratory infections (e.g., bacterial pneumonia or tuberculosis), allergic bronchopulmonary aspergillosis (ABPA), impairment of ciliary clearance (e.g., primary ciliary dyskinesia), and primary or secondary immunodeficiency, and it may also be associated with other diseases, such as chronic obstructive pulmonary disease (COPD) and severe asthma. Although the etiology of bronchiectasis is unknown in many cases, there is growing awareness regarding the importance of COPD as an underlying cause.

Table of Contents

1. Key Insights

2. Non-Cystic Fibrosis Bronchiectasis Overview at a Glance

  • 2.1. Patient Share (%) Distribution of NCFB in 2017
  • 2.2. Patients Share (%) Distribution of NCFB in 2030

3. Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Etiology and manifestations
  • 3.3. Symptoms
  • 3.4. Pathophysiology
  • 3.5. Diagnosis
  • 3.6. Prognosis

4. Treatment and management

5. Epidemiology and Patient Population

  • 5.1. Key Findings
  • 5.2. Total Prevalence of Non-cystic Fibrosis Bronchiectasis in 7MM

6. Country Wise-Epidemiology

  • 6.1. United States
    • 6.1.1. Assumptions and Rationale
    • 6.1.2. Prevalence of Non-cystic fibrosis bronchiectasis
    • 6.1.3. Diagnose prevalence of NCFB in United States
    • 6.1.4. Gender Specific Diagnosed prevalence NCFB in United States
    • 6.1.5. Severity Specific Diagnosed prevalence NCFB in United States
    • 6.1.6. Etiology associated with NCFB in United States
    • 6.1.7. Microbiology of NCFB patients in United States
  • 6.2. EU-5
    • 6.2.1. Assumptions and Rationale
    • 6.2.2. Germany
      • 6.2.2.1. Prevalence of Non-cystic fibrosis bronchiectasis
      • 6.2.2.2. Diagnose prevalence of NCFB in Germany
      • 6.2.2.3. Gender Specific Diagnosed prevalence NCFB in Germany
      • 6.2.2.4. Severity Specific Diagnosed prevalence NCFB in Germany
      • 6.2.2.5. Etiology associated with NCFB in Germany
      • 6.2.2.6. Microbiology of NCFB patients in Germany
    • 6.2.3. France
      • 6.2.3.1. Prevalence of Non-cystic fibrosis bronchiectasis in France
      • 6.2.3.2. Diagnose prevalence of NCFB in France
      • 6.2.3.3. Gender Specific Diagnosed prevalence NCFB in France
      • 6.2.3.4. Severity Specific Diagnosed prevalence NCFB in France
      • 6.2.3.5. Etiology associated with NCFB in France
      • 6.2.3.6. Microbiology of NCFB patients in France
    • 6.2.4. Italy
      • 6.2.4.1. Prevalence of Non-cystic fibrosis bronchiectasis in Italy
      • 6.2.4.2. Diagnose prevalence of NCFB in Italy
      • 6.2.4.3. Gender Specific Diagnosed prevalence NCFB in Italy
      • 6.2.4.4. Severity Specific Diagnosed prevalence NCFB in Italy
      • 6.2.4.5. Etiology associated with NCFB in Italy
      • 6.2.4.6. Microbiology of NCFB patients in Italy
    • 6.2.5. Spain
      • 6.2.5.1. Prevalence of Non-cystic fibrosis bronchiectasis in Spain
      • 6.2.5.2. Diagnose prevalence of NCFB in Spain
      • 6.2.5.3. Gender Specific Diagnosed prevalence NCFB in Spain
      • 6.2.5.4. Severity Specific Diagnosed prevalence NCFB in Spain
      • 6.2.5.5. Etiology associated with NCFB in Spain
      • 6.2.5.6. Microbiology of NCFB patients in Spain
    • 6.2.6. United Kingdom
      • 6.2.6.1. Prevalence of Non-cystic fibrosis bronchiectasis in the UK
      • 6.2.6.2. Diagnose prevalence of NCFB in the UK
      • 6.2.6.3. Gender Specific Diagnosed prevalence NCFB in UK
      • 6.2.6.4. Severity Specific Diagnosed prevalence NCFB in UK
      • 6.2.6.5. Etiology associated with NCFB in UK
      • 6.2.6.6. Microbiology of NCFB patients in UK
  • 6.3. Japan
    • 6.3.1. Assumptions and Rationale
    • 6.3.2. Prevalence of Non-cystic fibrosis bronchiectasis in Japan
    • 6.3.3. Diagnose prevalence of NCFB in Japan
    • 6.3.4. Gender Specific Diagnosed prevalence NCFB in Japan
    • 6.3.5. Severity Specific Diagnosed prevalence NCFB in Japan
    • 6.3.6. Etiology associated with NCFB in Japan
    • 6.3.7. Microbiology of NCFB patients in Japan

7. Unmet needs

8. Appendix

  • 8.1. Report Methodology

9. DelveInsight Capabilities

10. Disclaimer

11. About DelveInsight

Back to Top
전화 문의
F A Q